LETTERS

Central pontine myelinolysis temporally related to hypophosphataemia

Central pontine myelinolysis (CPM) is known to be associated with the rapid correction of severe hyponatraemia. However, there have been case reports of CPM occurring in normonatraemic patients.[1] Here we describe two patients in whom chronic alcohol abuse led to profound hypophosphataemia that was closely temporally related to the development of CPM.

Case 1

A 29 year old woman was admitted for investigation of painless jaundice of 10 days' duration. She had consumed 100–140 units of alcohol a week for the preceding 18 months and had been noted to have mildly deranged serum transaminase levels one year previously.

On admission she was fully oriented with normal speech and gait. She had a mild postural tremor but no asterixis. A plasma biochemical profile showed her sodium to be 122 mmol/l, potassium 2.1 mmol/l, and urea 5.9 mmol/l. Serum creatinine was 182 µmol/l, phosphate 0.65 mmol/l, magnesium 0.59 mmol/l, and total corrected calcium 2.18 mmol/l. She was immediately given potassium and magnesium supplements, chlordiazepoxide, and intravenous vitamins including vitamin K and thiamine.

Three days after admission she developed a *Staph aureus* septicaemia secondary to a peripheral venous cannula infection. This required treatment with intravenous cefuroxime and flucloxacillin. She subsequently became drowsy and by day 10 had developed a severe spastic dysarthria and profound spastic tetraparesis. There was a bilateral lower motor neurone pattern of facial weakness and gaze evoked nystagmus. The clinical suspicion of CPM was supported by magnetic resonance imaging of the brain, which showed symmetrical signal hyperintensity in the pons on T2 weighted images, as well as generalised cerebral atrophy.

A review of the biochemistry results during her admission showed that the maximum increase in serum sodium concentration over a 24 hour period was only 7 mmol/l (from 123 to 130 mmol/l). Potassium and magnesium concentrations were corrected to the lower end of their normal ranges. However, she developed profound hypophosphataemia (0.16 mmol/l at nadir) which was rapidly corrected to 0.8 mmol/l within 72 hours. The rapid rise in plasma phosphate coincided with the onset of the patient's neurological deterioration. With supportive care she made a gradual recovery such that two months after admission she was safe to be discharged, with only a mild residual left hemiparesis and slight spastic dysarthria, which were improving.

Case 2

A 44 year old woman was admitted with a three day history of progressive dysarthria, seven days of difficulty in walking, and dysaesthesia affecting all four limbs and the perioral region. She had consumed at least 80 units of alcohol a week for several months before presentation.

Examination on admission revealed a mild tetraparesis, dysarthria, and subjective sensory loss in both legs and the left arm. Her admission blood profile revealed a plasma sodium concentration of 136 mmol/l and potassium of 3.4 mmol/l. The serum phosphate concentration was profoundly low at 0.13 mmol/l. T2 weighted and FLAIR sequence MRI done three days after admission showed abnormal signal within the central brain stem suggestive of CPM (fig 1).

She was treated with oral thiamine, multivitamins, and minerals including phosphate. She made a rapid improvement such that her dysarthria had resolved and gait improved sufficiently for her to be discharged 11 days after admission.

Comment

The pathophysiology of CPM is not well understood. Rapid correction of severe hyponatraemia is frequently implicated as a causative factor, but CPM has been reported in the presence of normonatraemia,[1] hypokalemia,[2] and hypophosphataemia.[3] In these cases a hypothesis based on osmotic trauma must be questioned.

Recently an apoptotic hypothesis has been proposed.[4] It is suggested that a depletion of the energy supply to glial cells might limit the function of their Na^+/K^+-ATPase pumps. This could reduce their ability to adapt to relatively minor osmotic stress caused by small changes in serum sodium concentration, and ultimately lead to apoptosis. A preliminary study of necropsy material from five cases of CPM compared with controls has provided some support for this theory. Using immunohistochemistry, an imbalance was shown between proapoptotic and antiapoptotic factors in glial cells with the appearance of oligodendrocytes.[5] Furthermore the serum sodium concentrations in two of the patients remained normal from the onset of symptoms to the time of death.



Figure 1 Coronal FLAIR magnetic resonance image (MRI) (A) and axial T2 weighted MRI (B) from case 2, showing high signal within the pons consistent with central pontine myelinosis.

The two patients presented here showed aclose temporal association between severe hypophosphataemia and the development of CPM. Both patients abused alcohol, and the first patient had moderate hyponatraemia with hypokalaemia. They may therefore have been particularly susceptible to CPM for a variety of reasons. It is possible, however, that severe hypophosphataemia adversely affected the Na^+/K^+-ATPase pump and finally triggered apoptosis and CPM. The temporal association of neurological deterioration with the rapid correction of profound hypophosphataemia in case 1 is unlikely to relate to osmotic stress in view of the small contribution of phosphate towards total osmolarity. The rapid change in plasma phosphate may, however, increase cellular stress, contributing to eventual apoptosis.

Both patients described here made good recoveries with phosphate replacement and supportive care. This suggests that widespread apoptosis had not occurred. In these patients the speed and degree of recovery might reflect the resolution of pontine oedema that could accompany less widespread or incomplete apoptosis.

There are useful practical conclusions to be drawn from the observed association of CPM with hypophosphataemia. First, one must suspect the diagnosis of CPM in susceptible patients even without "typical" electrolyte abnormalities. Second, as severe hypophosphataemia in itself has been correlated with increased mortality[6] it would seem prudent to check and treat low serum phosphate concentrations in susceptible patients. This particularly refers to alcohol abusers or malnourished patients treated with intravenous glucose, diuretics, and steroids which may lower serum phosphate concentrations.

A W Michell, D J Burn, P J Reading
Regional Neurosciences Centre, Newcastle-upon-Tyne, UK

Correspondence to: Dr Michell; awmichell@hotmail.com

References

1 **Bernsen HJJA**, Prick MJJ. Improvement of central pontine myelinolysis as demonstrated by repeated magnetic resonance imaging in a patient without evidence of hyponatremia. *Acta Neurol Belg* 1999;**99**:189–93.
2 **Bähr M**, Sommer N, Petersen D, *et al*. Central pontine myelinolysis associated with low potassium levels in alcoholism. *J Neurol* 1990;**237**:275–6.
3 **De Broucker T**, Rueff B, Hammel P, *et al*. L'hypophosphorémie: cause possible de myélinolyse centropontine. *Presse Med* 1989;**18**:1166.
4 **Ashrafian H**, Davey P. A review of the causes of central pontine myelinolysis: yet another apoptotic illness? *Eur J Neurol* 2001;**8**:103–9.
5 **DeLuca GC**, Nagy Z, Esiri MM, *et al*. Evidence for a role for apoptosis in central pontine myelinolysis. *Acta Neuropathol* 2002:**103**:590–8.
6 **Halevy J**, Bulvik S. Severe hypophosphatemia in hospitalized patients. *Arch Intern Med* 1988;**148**:153–5.

Spastic movement disorder: what is the impact of research on clinical practice?

One expects that convincing research results would have an impact on clinical practice. However, whether or not a new concept becomes transferred to an application in clinical practice is dependent on the medical

field and on the therapeutic consequences. The issue discussed here concerns spasticity, a common motor disorder in, for example, patients who have had a stroke or a spinal cord injury.

The traditional concept

Over many years it was widely accepted that spasticity consists of muscle hypertonia (that is, "a velocity dependent resistance of a muscle to stretch"[1]) caused by exaggerated reflexes, leading to the spastic movement disorder.[2] This concept was based on animal experiments (for example, in the decerebrate cat[3]) and on the physical signs evident on clinical examination at the bedside. Consequently, the aim of any treatment was to reduce reflex activity by antispastic drugs. Possible differences in pathophysiology between the clinical signs of spasticity and the spastic movement disorder which hampers the patient were not considered.

The new concept

Early clinical observations[4] and studies in the 1980s on spastic movement disorders[5] clearly failed to support the traditional concept. In the subsequent 20 years an increasing number of studies using different technological approaches with electromyographic (EMG) and biomechanical recordings focused on the relation between muscle EMG and reflex activity and muscle tone during various functional[6–8] and clinical[9–12] conditions. All these studies fused into a new concept of spasticity (reviewed in several articles[13–15]). This concept has never been questioned in its basic aspects.

The new concept was based on the following observations. First, in the active muscle (that is, during movement) the presence of exaggerated tendon tap reflexes is associated with a loss of the functionally essential polysynaptic or longer latency reflexes, with the consequence that overall muscle activity is reduced during functional movements. Second, as a response to the primary lesion, changes in non-neuronal factors (muscle and connective tissue) compensate for the loss of supraspinal drive and essentially contribute to spastic hypertonia in both passive[9 12] and active[8] muscles.

The *scientific consequence* of this is that the physical signs obtained during the clinical bedside examination are an epiphenomenon rather than the cause of the functional condition (which impairs the patient). During movement, essential reflex mechanisms are involved which cannot usually be assessed by clinical testing. Consequently, the clinical examination required for diagnostic purposes has to be separated from functional testing, which should determine the therapeutic approach. For example, motor function can be assessed by a walking index, such as WISCI.[16]

The *therapeutic consequence* of these observations is that antispastic drugs should be used only with caution in the mobile spastic patient, as a decrease in muscle tone achieved by these drugs could be associated with an accentuation of paresis, impairing the performance of functional movements.[17 18] Consequently, spastic muscle tone is required so that a patient can walk again after a stroke.

Facts and consequences

Although this new concept has become well established scientifically in journals with a mainly scientific orientation during the past 20 years, there has been little transfer to clinical practice. This is reflected in recent review articles in journals with a practical orientation[19–21] read predominantly by clinical neurologists.

The following factors may contribute to the persistence of some old fashioned concepts in clinical neurology:

- The old concept was simple to understand and had a clear therapeutic consequence: the prescription of antispastic drugs. It is seemingly logical that exaggerated reflexes cause muscle hypertonia. The new concept is more complex and its implications—that antispastic drugs should *not* generally be used—make the doctor somewhat resourceless.
- It is not rewarding for a neurologist to take care of patients after a stroke and to have to explain that there are limited therapeutic options (that is, that it will be impossible to restore normal function, and that physical exercises will be more helpful than drug treatment).
- It is, of course of no interest for companies producing antispastic drugs to support graduate medical education in this new concept, with its limited opportunities for drug treatment.

The *consequences* of this experience should be as follows. First, scientific research results should be translated into an understandable and pragmatic format, to convince doctors and patients of the superiority of the new concept. Second, such a novel concept should initiate the development of new forms of treatment (for example, in the field of active physiotherapy); at very least it should be associated with a well structured physical treatment programme which allows the doctor to become involved. Third, the concept should emphasise that immobilised patients may benefit from the use of antispastic drugs (for example, in the management of spasms and for easier nursing); this would make the concept more acceptable to the drug companies. Finally, the concept should include perspectives and limitations of any possible achievements.

V Dietz

ParaCare, Institute for Rehabilitation and Research, University Hospital Balgrist, Forchstr 340, 8008 Zurich, Switzerland

Competing interests: none declared

Correspondence to: Professor Dr V Dietz; dietz@balgrist.unizh.ch

References

1 **Lance JW**. Symposium synopsis. In: Feldmann RG, Young RR, Koella WP, eds. *Spasticity: disordered motor control*. Chicago: Year Book Medical Publishers, 1980:485–95.
2 **Denny-Brown D**. Historical aspects of the relation of spasticity to movements. In: Feldmann RG, Young RR, Koella WP, Eds. *Spasticity: disordered movement control*. Chicago: Year Book Medical Publishers, 1980:1–15.
3 **Sherrington CS**. *The integrative action of the nervous system*. New Haven: Yale University Press, 1906.
4 **Landau WM**. Spasticity: the fable of a neurological demon and the emperor's new therapy. *Arch Neurol* 1974;**31**:217–19.
5 **Dietz V**, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. *Brain* 1981;**104**:431–49.
6 **Sinkjaer T**, Andersen JB, Nielsen JF. Impaired stretch reflex and joint torque modulation during spastic gait in multiple sclerosis patients. *J Neurol* 1996;**243**:566–74.
7 **Dietz V**, Trippel M, Berger W. Reflex activity and muscle tone during elbow movements of patients with spastic paresis. *Ann Neurol* 1991;**80**:767–84.
8 **Ibrahim IK**, Berger W, Trippel M, *et al*. Stretch-induced electromyographic activity and torque in spastic elbow muscles. *Brain* 1993;**116**:972–89.
9 **O'Dwyer NJ**, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. *Brain* 1996;**119**:1737–49.
10 **O'Dwyer NJ**, Ada L. Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. *Curr Opin Neurol* 1996;**9**:451–5.
11 **Powers RK**, Marder-Meyer J, Rymer WZ. Quantitative relations between hypertonia and stretch reflex threshold in spastic hemiparesis. *Ann Neurol* 1988;**23**:115–24.
12 **Hiersemenzel LP**, Curt A, Dietz V. From spinal shock to spasticity. Neuronal adaptations to spinal cord injury. *Neurology* 2000;**54**:1574–82.
13 **Dietz V**. Human neuronal control of automatic functional movements: interaction between central programs and afferent input. *Physiol Rev* 1992;**72**:33–69.
14 **Dietz V**. Supraspinal pathways and the development of muscle-tone dysregulation [annotation]. *Dev Med Child Neurol* 1999;**41**:708–15.
15 **Dietz V**. Proprioception and locomotor disorders. *Nat Rev Neurosci* 2002;**3**:781–90.
16 **Ditunno JF**, Ditunno PL, Graziani V, *et al*. Walking index for spinal injury (WISCI): an international multicenter validity and reliability study. *Spinal Cord* 2000;**38**:234–43.
17 **Hoogstraaten MC**, van der Ploeg RJ, van der Burg W, *et al*. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. *Acta Neurol Scand* 1988;**77**:224–30.
18 **Steinbock P**, Reiner AM, Beauchamp R, *et al*. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. *Dev Med Child Neurol* 1997;**39**:278–84.
19 **Sheean G**. The pathophysiology of spasticity. *Eur J Neurol* 2002;**9**:3–8.
20 **Abbruzzese G**. The medical management of spasticity. *Eur J Neurol* 2002;**9**:30–4.
21 **Gracies JM**. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. *Phys Med Rehabil Clin* 2001;**12**:747–68.

Intracranial hypotension after chiropractic manipulation of the cervical spine

The aetiology of intracranial hypotension is not fully understood, but CSF leakage from spinal meningeal diverticula or dural tears may be involved. In the majority of patients without a history of mechanical opening of the dura the cause of intracranial hypotension is unknown and the syndrome is termed "spontaneous" intracranial hypotension. We report a case of intracranial hypotension ensuing after a spinal chiropractic manipulation leading to CSF isodense effusion in the upper cervical spine.

Case report

A 40 year old woman undertook a spinal chiropractic manipulation. The chiropractioner grasped the head of the supine patient and exerted axial tension while rotating the head. During this manoeuvre the patient complained of a sudden sharp pain in her upper neck, and the procedure had to be stopped immediately. Subsequently she complained of headaches and after 24 hours she developed nausea and vomiting. Her headaches worsened, and lying down gave the only measure of limited relief. On the sixth day she developed double vision and presented to the neurology department of a community hospital.

She had a right abducens palsy and pachymeningeal gadolinium enhancement on magnetic resonance imaging (MRI). The first